SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending following an official determination from NOAA that its deep-seabed mining application is in full compliance, a key milestone that clarifies the regulatory path toward commercial operations. Community members are actively debating the significance of this news for long-term permitting and discussing whether the stock is positioned for a sustained rally despite recent volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings Inc. (CELH) is experiencing extreme volatility as shares touch new 52-week lows, fueling intense community debate regarding institutional manipulation versus fundamental concerns like competition from private-label alternatives. Investors are closely monitoring the upcoming earnings release, with many split between those expecting a massive post-earnings rebound and those fearing further downside due to inventory and margin pressures.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant retail and institutional interest, fueled by a positive feature in the Wall Street Journal and community enthusiasm surrounding the company's expanding role in physical AI, robotics, and its QNX software platform. Investors are closely monitoring volume and price action as the community discusses potential breakouts, institutional accumulation, and the stock's long-term growth potential in cybersecurity and automotive technology.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after announcing a strategic manufacturing partnership with Cellipont Bioservices to advance its ERNA-101 ovarian cancer therapy toward clinical trials. While some investors are excited by the potential for a short squeeze given the stock's low float and high volume, others remain skeptical, citing concerns over historical dilution and the speculative nature of early-stage biotech.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is experiencing significant volatility as retail investors debate the company's long-term viability and the impact of its partnership with Disney, while the stock faces heavy short interest and skepticism regarding management's profitability targets. The community remains deeply polarized, with bulls pointing to potential strategic synergies and oversold conditions, while bears cite historical subscriber losses and a lack of insider buying as reasons to avoid the stock.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense retail speculation as the community positions itself for upcoming earnings, with bulls betting that new management's strategic shift will trigger a parabolic move. Investors are actively debating the potential for a short squeeze, bolstered by optimism around housing market trends and aggressive accumulation of shares ahead of the official report.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following an earnings report that emphasized improved profit margins and robust AI infrastructure demand, helping to alleviate concerns regarding recent legal and regulatory overhangs. Investors and community members are actively debating the company's valuation gap compared to sector peers and monitoring whether this momentum can sustain a potential short squeeze.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and community debate as investors weigh the company's recent siRNA pipeline updates and Elevidys revenue growth against ongoing regulatory scrutiny and analyst skepticism regarding clinical data. The stock is currently a major focus for traders discussing potential short-squeeze dynamics and the long-term outlook for its Duchenne muscular dystrophy gene therapy franchise.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is facing significant volatility following its latest earnings report, where strong revenue growth and raised guidance are being offset by concerns regarding supply chain constraints and margin pressure. Despite the post-earnings sell-off, the community remains divided between those viewing the pullback as a buying opportunity given the firm's critical role in the AI data center buildout and those concerned that the stock's high valuation leaves it vulnerable to further correction.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and intense social media discussion as investors debate its valuation ahead of upcoming earnings, with bull-case optimism centering on potential government contracts and strategic acquisitions while bears express concerns over cash burn and dilution. Traders are heavily focused on the stock's recent price swings and potential for a short squeeze, leading to a highly polarized community dialogue regarding the company's long-term quantum computing prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Shares Of SeaStar Medical Today?

Shares of SeaStar Medical Holding Corporation (NASDAQ: ICU) are trading lower Friday after the company initiated a reverse stock split.read more...

A Glimpse of SeaStar Medical Holding's Earnings Potential

SeaStar Medical Holding Corp. shares rose 7% to their highest level in more than three months on Wednesday after the company said an independent safety board had reviewed early data and recommended continuing its pivotal trial of a kidney failure therapy.However, the stock&nbsp;crashed 46% in after-hours trading on Wednesday.The Data Safety Monitoring Board (DSMB) conducted an interim review of the first 100 patients in the Neutralize-AKI study of the company’s Selective Cytopheretic Device (SCD) in adults with acute kidney injury requiring continuous renal replacement therapy.&nbsp;The panel found no device-related safety concerns and reported zero adverse events tied to the treatment. It also flagged a signal of potential clinical benefit across key measures.To boost the statistical power of the trial, the DSMB recommended increasing enrollment from 200 to 339 patients. SeaStar said 137 patients have already been enrolled and expects to complete recruitment near the end of 2026. The company plans to accelerate enrollment by adding new trial sites.The Neutralize-AKI trial will measure a composite of 90-day mortality or dialysis dependency, with additional endpoints including 28-day mortality, ICU-free days, and dialysis dependency at one year. Subgroup analyses will evaluate patients with sepsis and acute respiratory distress syndrome.SeaStar’s SCD therapy, marketed as Quelimmune, is already approved by the FDA for life-threatening acute kidney injury in children with sepsis or septic conditions. Early real-world registry data showed no safety concerns and a 75% survival rate at 28 days, suggesting a possible reduction in mortality compared with historical outcomes.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that warrant holders had timed the news to capitalize on the stock’s spike, noting they could profit as long as shares remained above their average price and questioning whether the market could absorb the additional supply.<stembedurl>https://stocktwits.com/alphaonetrading/message/629922155</stembedurl>Another user said the recent price surge was only the beginning, arguing that strong safety signals from the trial support future runs and calling any near-term pullback a buying opportunity for the long term.<stembedurl>https://stocktwits.com/MasheredTrader/message/629918153</stembedurl><a href="https://stocktwits.com/symbol/ICU">SeaStar Medical’s stock</a> has declined 36.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

SeaStar Medical Stock Jumps On Safety Board Backing For Kidney Trial; Retail Eyes Another Run Despite After-Hours Plunge

SeaStar’s SCD therapy, marketed as Quelimmune, is already approved by the FDA for life-threatening acute kidney injury in children with sepsis or septic conditions.

Equity

The trial’s enrollment target has been raised to 339 patients, with completion expected by late 2026.

Shares of SeaStar Medical Holding Corporation (ICU) slumped 61% on Friday afternoon after the healthcare company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.seastarmedical.com/news/news-details/2025/SeaStar-Medical-Announces-Pricing-of-Up-to-8-Million-Public-Offering/default.aspx">announced</a> the pricing of a public offering of over six million shares of its common stock at $0.65.The offer price of $0.65 represents a 33% discount on the stock’s closing price on Wednesday.The gross proceeds to the company from the offering are expected to be approximately $4 million, before deducting the placement agent’s fees and other offering expenses payable. SeaStar said it intends to use the net proceeds from the offering for general corporate purposes. The offering is expected to close on or about June 23, 2025.SeaStar Medical is a commercial-stage healthcare company focused on treatments for critically ill patients facing organ failure and potential loss of life.Its Quelimmune product was approved by the U.S. Food and Drug Administration (FDA) last year for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients.On Stocktwits, retail sentiment around SeaStar rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:622/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_1_11_54_PM_png_87eaa0be26.webp" alt="ICU's Sentiment Meter and Message Volume as of 1:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="622" height="64"><figcaption>ICU's Sentiment Meter and Message Volume as of 1:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed dissatisfaction with the lack of clarity around the management’s decisions.<stembedurl>https://stocktwits.com/Saxon_stock/message/618487152</stembedurl>Another opined that the company is inching close to bankruptcy.<stembedurl>https://stocktwits.com/Cowsheeptheone/message/618483251</stembedurl><a href="https://stocktwits.com/symbol/ICU">ICU stock</a> is down by 81% this year and by over 93% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-ends-kia-soul-same-day-delivery-program/chlxYXvRRPx">Amazon Ends Same-Day Deliveries Via Kia Souls, Leans On Its Network Of Gig Workers: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SeaStar Medical Stock Tanks At Discounted Pricing Of Public Offering, Retail Believes Company Is Inching Closer To Bankruptcy

The public offer price of $0.65 represents a 33% discount on the stock’s closing price on Wednesday.

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

SeaStar Medical Holding Corp

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$4.89
Prev Close	$4.42
Open	$4.40
Dividend Yield	0.00%
50-Day Moving Average	$3.34
Beta	0.25
Avg. Volume	129,730.82
PE Ratio	-0.54

52-Week High	$13.40
52-Week Low	$2.07
Market Capitalization	$17.65M
EPS (Annual)	-$5.86
Price to Book	1.63
Revenue Per Employee	$72,588.24

ICU
SeaStar Medical Holding Corp

Feed

News

Sentiment

Fundamentals

Info

Latest ICU News

ICUSeaStar Medical Holding Corp